What Is Pegvaliase?
Pegvaliase is an FDA-approved medication for Phenylketonuria (PKU), a rare genetic disorder. In individuals with PKU, the body cannot properly break down phenylalanine, an amino acid found in protein-rich foods. This leads to a buildup of phenylalanine in the blood, which can cause significant neurological and developmental issues if not managed.
Pegvaliase, also known by its brand name Palynziq, acts as an enzyme replacement therapy. It works by providing an external enzyme that helps to metabolize and reduce the levels of phenylalanine in the body. This medication is administered through subcutaneous injection, with dosing guided by U.S. Prescribing Information and the clinical judgment of healthcare professionals. A total of 8 clinical trials have investigated pegvaliase, focusing on its effectiveness and safety for patients with PKU, including those with Maternal Phenylketonuria.
Uses and Conditions Under Study
Pegvaliase is primarily studied for the treatment of Phenylketonuria (PKU), a rare inherited metabolic disorder. Individuals with PKU lack a functional enzyme needed to break down phenylalanine, an amino acid found in most protein-containing foods. This deficiency leads to a buildup of phenylalanine in the blood, which can result in severe neurological and developmental issues if not properly managed through diet or medication.
The vast majority of clinical investigations, encompassing 7 out of 8 trials, focus on various forms of Phenylketonuria. These studies explore how pegvaliase can help reduce phenylalanine levels in patients, aiming to improve metabolic control and prevent long-term complications. These trials include different patient groups, such as those who are "Palynziq naïve" (new to the treatment) and "Palynziq experienced" (already on treatment).
A specific trial is dedicated to Maternal Phenylketonuria. This condition is critical because high phenylalanine levels in a pregnant woman with PKU can severely impact the developing fetus. This particular study aims to assess the safety and efficacy of pegvaliase in managing phenylalanine levels during pregnancy. Additionally, one observational study gathers important safety data from pregnant women who were exposed to pegvaliase, contributing to a comprehensive understanding of the drug's profile in this population.
Dosing
Pegvaliase, known by its brand name Palynziq, is administered as a subcutaneous injection. The specific dosage and frequency are determined by the prescribing information and the clinical judgment of the healthcare provider, tailored to the individual patient's needs.
Clinical trials have investigated a range of strengths for pegvaliase. Participants in these studies have self-administered doses including 2.5 mg, 10 mg, 20 mg, 40 mg, and 60 mg. The frequency of administration has varied, with some participants taking the medication from 1 time up to 7 times a week, depending on the study protocol and individual requirements.
The studies have included different patient populations based on their prior treatment experience, such as those who are "Palynziq naïve" (meaning they have not previously received Palynziq) and "Palynziq experienced" (those who have prior experience with the medication). While specific adult versus pediatric doses are not detailed in the trial data, dosing is generally individualized to achieve optimal phenylalanine control.
Side Effects
Specific information regarding the types of side effects and their frequency compared to a placebo for Pegvaliase is not available in the provided data. Clinical trial NCT03694353, which evaluated the safety and efficacy of self-administered injections of Pegvaliase in adults with Phenylketonuria (PKU), reported on the number of participants who experienced treatment-emergent adverse events (TEAEs).
Treatment-emergent adverse events are any undesirable experiences that occur or worsen during the course of a clinical trial. In this study, various counts of participants were reported to have experienced TEAEs. The highest number of participants reported to experience a treatment-emergent adverse event was 36 participants. Other reported counts of participants experiencing TEAEs were 17 participants, 7 participants, and 1 participant. These numbers indicate the occurrence of adverse events among the study population. However, without additional details on the specific nature, severity, or frequency of these events, or the total number of participants in the study arm, a comprehensive list of common side effects or their percentages cannot be provided from this data.
Clinical Trial Results
Pegvaliase for Phenylketonuria (PKU)
The efficacy of Pegvaliase was investigated in clinical trial NCT03694353, a study focused on the safety and efficacy of self-administered injections of Pegvaliase at doses greater than 40 mg/day in adults with Phenylketonuria (PKU). PKU is a genetic disorder where the body cannot properly break down phenylalanine (Phe), an amino acid found in many foods. High levels of Phe can lead to serious health problems, so reducing blood Phe concentration is a primary goal of treatment.
A key outcome measured in this trial was the change in blood Phe concentration. The study observed various mean changes in blood Phe concentration across different measurements or analyses for all subjects. The majority of these measurements indicated a significant reduction in blood Phe levels. Specifically, observed mean reductions in blood Phe concentration ranged from -761 µmol/L to -1319 µmol/L. These negative values signify an improvement in Phe control, with larger negative numbers indicating a greater reduction in circulating phenylalanine.
While most measurements showed a decrease, one instance reported a mean increase in blood Phe concentration of 1376.9 µmol/L. Despite this variability, the predominant finding was that treatment with Pegvaliase led to a decrease in blood phenylalanine levels in adults with PKU. These results suggest that Pegvaliase has the potential to help manage Phe levels, which is crucial for mitigating the long-term health consequences associated with PKU.
Currently Recruiting Trials
Several clinical trials for Palynziq (pegvaliase) are actively seeking participants to further understand its long-term effects and safety profile in patients with Phenylketonuria (PKU). These studies aim to gather crucial information about how the treatment impacts individuals over time, including specific populations like pregnant women.
One ongoing study, NCT06305234, known as PALisade, is a 10-year observational study evaluating the immune response and other laboratory parameters in patients receiving long-term Palynziq treatment for PKU in the United States. This study is sponsored by BioMarin Pharmaceutical and aims to enroll up to 200 participants.
Another important trial, NCT05579548, is a global, multicenter observational study focusing on maternal, fetal, and infant outcomes when Palynziq is used during pregnancy and breastfeeding. This Phase 4 study, also sponsored by BioMarin Pharmaceutical, seeks to enroll 50 participants to assess the impact on both mothers with PKU and their offspring.
Finally, the PALace study, NCT05813678, is a global, 10-year observational study designed to further characterize the long-term safety and tolerability of pegvaliase in patients with PKU. This study, sponsored by BioMarin Pharmaceutical, will also investigate hypersensitivity reactions and the effectiveness of risk minimization measures, particularly in the European Union. It plans to enroll up to 450 patients.
Where to Participate
Clinical trials for pegvaliase are conducted across a wide geographic area, with study sites located in 18 different locations spanning 13 cities and 13 states. This broad reach helps ensure diverse participation and accessibility for patients interested in contributing to research.
Some of the top cities with multiple participating sites include:
- Aurora, Colorado
- Atlanta, Georgia
- Chicago, Illinois
- Indianapolis, Indiana
- New Orleans, Louisiana
- Boston, Massachusetts
- Dallas, Texas
- Milwaukee, Wisconsin
- Portland, Oregon
- Pittsburgh, Pennsylvania
Eligibility for these studies generally includes individuals of all genders, and children are welcome to participate. However, healthy volunteers are not being recruited for these specific trials, as the focus is on patients living with Phenylketonuria.
Development Timeline
The journey of pegvaliase in clinical development began with its first trial on October 3, 2018. Initially, the research explored conditions such as Irritable Bowel Syndrome with Constipation (IBS-C) and hyperphosphatemia. However, the development pipeline soon expanded and focused primarily on Phenylketonuria (PKU), including studies specifically addressing maternal PKU.
Over time, a total of 8 clinical trials have been initiated for pegvaliase, involving a combined enrollment of 828 participants. The majority of these studies were sponsored by BioMarin Pharmaceutical, which has driven much of the drug's research and development. Other institutions, such as Boston Children's Hospital and the University of Missouri-Columbia, have also contributed to the early research efforts.
The development has progressed through various phases, including two Phase 3 trials and one Phase 4 trial, alongside several observational studies. The latest trial is projected to conclude in March 2026, marking a continuous commitment to understanding the long-term effects and benefits of pegvaliase for patients.